| Trial ID: | L1923 |
| Source ID: | NCT01167231
|
| Associated Drug: |
Acarbose (Glucobay, Bayg5421)
|
| Title: |
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
|
| Acronym: |
ABDOMEN
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: Acarbose (Glucobay, BAYG5421)
|
| Outcome Measures: |
Primary: Safety, tolerability of acarbose and its effect on body weight, waist circumference and blood pressure, approximately 6 months after acarbose treatment initiation | Secondary: Effect of acarbose on HbA1c, fasting and postprandial glycemia and on lipid profile, approximately 6 months after acarbose treatment initiation
|
| Sponsor/Collaborators: |
Sponsor: Bayer
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
3310
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2007-05
|
| Completion Date: |
2008-06
|
| Results First Posted: |
|
| Last Update Posted: |
2010-08-25
|
| Locations: |
Many Locations, Poland
|
| URL: |
https://clinicaltrials.gov/show/NCT01167231
|
